CD49d is the strongest flow cytometry-based predictor of overall survival in chronic lymphocytic leukemia

Journal of Clinical Oncology

Volumn 32, Issue 9, 2014, Pages 897-904

  Bulian, Pietro ^a   Shanafelt, Tait D ^e   Fegan, Chris ^f   Zucchetto, Antonella ^a   Cro, Lilla ^b   Nuc̈kel, Holger ^g   Baldini, Luca ^b   Kurtova, Antonina V ^h   Ferrajoli, Alessandra ^h   Burger, Jan A ^h   Gaidano, Gianluca ^c   Del Poeta, Giovanni ^d   Pepper, Chris ^f   Rossi, Davide ^c   Gattei, Valter ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e Mayo Research Center   (United States)

^f CARDIFF UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA4 INTEGRIN; CD38 ANTIGEN; PROTEIN KINASE ZAP 70; TUMOR MARKER; ZAP70 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONFOUNDING VARIABLE; EARLY CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFERENCE VALUE; SURVIVAL RATE; TREATMENT FREE SURVIVAL; VALIDATION STUDY; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; MULTICENTER STUDY; PREDICTIVE VALUE; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RISK;

ANTIGENS, CD38; DISEASE-FREE SURVIVAL; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTEGRIN ALPHA4; KAPLAN-MEIER ESTIMATE; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 84899742457     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.50.8515     Document Type: Article

References (43)

1. Chiorazzi N, Rai KR, Ferrarini M: Chronic lymphocytic leukemia. N Engl J Med 352:804-815, 2005
2. Damle RN, Wasil T, Fais F, et al: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94:1840-1847, 1999 (Pubitemid 29430399)
3. Hamblin TJ, Davis Z, Gardiner A, et al: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999 (Pubitemid 29430400)
4. Kröber A, Seiler T, Benner A, et al: V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 100:1410-1416, 2002 (Pubitemid 34864299)
5. Döhner H, Stilgenbauer S, Benner A, et al: Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000 (Pubitemid 32064784)
6. Hamblin TJ, Orchard JA, Ibbotson RE, et al: CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 99:1023-1029, 2002 (Pubitemid 34525567)
7. Crespo M, Bosch F, Villamor N, et al: ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 348:1764-1775, 2003 (Pubitemid 36514707)
8. Rassenti LZ, Huynh L, Toy TL, et al: ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 351:893-901, 2004 (Pubitemid 39096916)
9. Rassenti LZ, Jain S, Keating MJ, et al: Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. Blood 112:1923-1930, 2008
10. Burger JA: Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape. Curr Opin Oncol 24:643-649, 2012
11. Zucchetto A, Bomben R, Dal Bo M, et al: CD49d in B-cell chronic lymphocytic leukemia: Correlated expression with CD38 and prognostic relevance. Leukemia 20:523-525, 2006; author reply 528-529
12. Zucchetto A, Vaisitti T, Benedetti D, et al: The CD49d/CD29 complex is physically and functionally associated with CD38 in B-cell chronic lymphocytic leukemia cells. Leukemia 26:1301-1312, 2012
13. Woyach JA, Johnson AJ, Byrd JC: The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120:1175-1184, 2012
14. Gattei V, Bulian P, Del Principe MI, et al: Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 111:865-873, 2008
15. Shanafelt TD, Geyer SM, Bone ND, et al: CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: A prognostic parameter with therapeutic potential. Br J Haematol 140:537-546, 2008 (Pubitemid 351230080)
16. Rossi D, Zucchetto A, Rossi FM, et al: CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 93:1575-1579, 2008
17. Nückel H, Switala M, Collins CH, et al: High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol 131:472-480, 2009
18. Cro L, Ferrario A, Lionetti M, et al: The clinical and biological features of a series of immunophenotypic variant of B-CLL. Eur J Haematol 85:120-129, 2010
19. Shanafelt TD, Drake MT, Maurer MJ, et al: Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia. Blood 117:1492-1498, 2011
20. Majid A, Lin TT, Best G, et al: CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL. Leuk Res 35:750-756, 2011
21. Blettner M, Sauerbrei W, Schlehofer B, et al: Traditional reviews, meta-analyses and pooled analyses in epidemiology. Int J Epidemiol 28:1-9, 1999 (Pubitemid 29086203)
22. Barza M, Trikalinos TA, Lau J: Statistical considerations in meta-analysis. Infect Dis Clin North Am 23:195-210, 2009
23. Katsahian S, Latouche A, Mary JY, et al: Practical methodology of meta-analysis of individual patient data using a survival outcome. Contemp Clin Trials 29:220-230, 2008 (Pubitemid 351248769)
24. Harrell FE Jr, Lee KL, Mark DB: Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15:361-387, 1996 (Pubitemid 26072233)
25. Harrell FE: Regression Modeling Strategies. New York, NY, Springer, 2001
26. Pencina MJ, D'Agostino RB Sr, Steyerberg EW: Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 30:11-21, 2011
27. Therneau T, Atkinson E: Technical Report Series No. 61: An Introduction to Recursive Partitioning Using the RPART Routines. Rochester, MN, Department of Health Science Research, Mayo Clinic, 1997
28. Venables W, Ripley B: Modern Applied Statistics With S. New York, NY, Springer-Verlag, 2002
29. Ishwaran H, Koglaur UB, Blackstone EH, et al: Random survival forests. Ann Appl Stat 2:841-860, 2008
30. Kurtova A, Sivina M, Quiroga M, et al: The immunophenotype signature CD49d+CD38+ identifies chronic lymphocytic leukemia cases with a higher potential for migration beneath marrow stromal cell. Blood 114, 2009 (abstr 356)
31. Shanafelt TD, Hanson C, Dewald GW, et al: Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol 26:e5-e6, 2008
32. Williams B, Mandrekar J, Mandrekar S, et al: Technical Report Series No. 79: Finding Optimal Cutpoints for Continuous Covariates With Binary and Time-to-Event Outcomes. Rochester, MN, Department of Health Science Research, Mayo Clinic, 2006
33. Oscier DG, Gardiner AC, Mould SJ, et al: Multivariate analysis of prognostic factors in CLL: Clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 100:1177-1184, 2002 (Pubitemid 34864269)
34. Del Poeta G, Maurillo L, Venditti A, et al: Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 98:2633-2639, 2001
35. Kröber A, Bloehdorn J, Hafner S, et al: Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 24:969-975, 2006 (Pubitemid 46646223)
36. Josefsson P, Geisler CH, Leffers H, et al: CLLU1 expression analysis adds prognostic information to risk prediction in chronic lymphocytic leukemia. Blood 109:4973-4979, 2007 (Pubitemid 46827796)
37. Pepper C, Majid A, Lin TT, et al: Defining the prognosis of early stage chronic lymphocytic leukaemia patients. Br J Haematol 156:499-507, 2012
38. Orchard JA, Ibbotson RE, Davis Z, et al: ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 363:105-111, 2004 (Pubitemid 38068326)
39. Lucio PJ, Faria MT, Pinto AM, et al: Expression of adhesion molecules in chronic B-cell lymphoproliferative disorders. Haematologica 83:104-111, 1998 (Pubitemid 28180603)
40. Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31:88-94, 2013
41. Spaargaren M, Beuling EA, Rurup ML, et al: The B cell antigen receptor controls integrin activity through btk and PLCgamma2. J Exp Med 198:1539-1550, 2003 (Pubitemid 37467168)
42. de Rooij MF, Kuil A, Geest CR, et al: The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 119:2590-2594, 2012
43. Ponader S, Chen SS, Buggy JJ, et al: The bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182-1189, 2012